基础血糖可控,但餐后问题持续存在——这是下一个目标!
基础和餐后血糖升高共同导致糖尿病高血糖暴露,但当前治疗主要有效控制基础部分。餐后高血糖控制不佳限制诊断后5至10年后的整体血糖控制成功,并与胰岛素治疗常见的体重增加相关。本文综述相关主题并建议将更多资源用于餐后问题的基础和临床研究。
要点
- 当前治疗主要有效控制基础血糖,餐后高血糖控制不佳限制长期整体血糖控制。
- 餐后问题包括葡萄糖及其他代谢物异常、体重增加和低血糖风险。
- 短期GLP-1激动剂或普兰林肽在特定情况下可有效控制2型糖尿病餐后高血糖。
核心结论
- 餐后问题应得到更多关注,建议将更多可用资源用于餐后问题的基础和临床研究。
研究设计与样本
- 本文为综述,检索范围未报告。
主要发现
- 基础和餐后血糖升高共同导致糖尿病高血糖暴露,但当前治疗主要有效控制基础部分。
- 无法控制餐后高血糖限制诊断后5至10年后维持整体血糖控制的成功,并与胰岛素治疗期间常见的体重增加相关。
- 餐后问题包括葡萄糖及其他代谢物异常、体重增加和低血糖风险。
- 短期胰高血糖素样肽1激动剂或淀粉样肽激动剂普兰林肽在特定情况下可非常有效控制2型糖尿病餐后高血糖。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Both basal and postprandial elevations contribute to the hyperglycemic exposure of diabetes, but current therapies are mainly effective in controlling the basal component. Inability to control postprandial hyperglycemia limits success in maintaining overall glycemic control beyond the first 5 to 10 years after diagnosis, and it is also related to the weight gain that is common during insulin therapy. The "prandial problem"-comprising abnormalities of glucose and other metabolites, weight gain, and risk of hypoglycemia-deserves more attention. Several approaches to prandial abnormalities have recently been studied, but the patient populations for which they are best suited and the best ways of using them remain incompletely defined. Encouragingly, several proof-of-concept studies suggest that short-acting glucagon-like peptide 1 agonists or the amylin agonist pramlintide can be very effective in controlling postprandial hyperglycemia in type 2 diabetes in specific settings. This article reviews these topics and proposes that a greater proportion of available resources be directed to basic and clinical research on the prandial problem.
引用
- Riddle MC. Basal Glucose Can Be Controlled, but the Prandial Problem Persists-It's the Next Target! Diabetes Care. 2017. PMID: 28223444. doi:10.2337/dc16-2380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。